Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity

[1]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[2]  E. Wherry,et al.  Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. , 2018, Cancer cell.

[3]  S. Asthana,et al.  A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.

[4]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[5]  Scott N. Mueller,et al.  Migratory CD11b+ conventional dendritic cells induce T follicular helper cell–dependent antibody responses , 2017, Science Immunology.

[6]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[7]  Ronald N Germain,et al.  Dendritic cell and antigen dispersal landscapes regulate T cell immunity , 2017, The Journal of experimental medicine.

[8]  Dana Pe’er,et al.  Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade , 2017, Cell.

[9]  S. Wienert,et al.  T Cell Zone Resident Macrophages Silently Dispose of Apoptotic Cells in the Lymph Node , 2017, Immunity.

[10]  Charles H. Yoon,et al.  IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment , 2017, Cell.

[11]  Christina S. Leslie,et al.  Chromatin states define tumor-specific T cell dysfunction and reprogramming , 2017, Nature.

[12]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[13]  Benjamin D. Greenbaum,et al.  Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses , 2017, Cell.

[14]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[15]  N. Hacohen,et al.  Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors , 2017, Science.

[16]  L. Boon,et al.  The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity , 2016, Nature Communications.

[17]  S. Berger,et al.  Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade , 2016, Science.

[18]  G. Hammer,et al.  Inflammatory Th1 and Th17 in the Intestine Are Each Driven by Functionally Specialized Dendritic Cells with Distinct Requirements for MyD88. , 2016, Cell reports.

[19]  A. Hakimi,et al.  The head and neck cancer immune landscape and its immunotherapeutic implications. , 2016, JCI insight.

[20]  A. Iwasaki,et al.  CD301b+ dendritic cells suppress T follicular helper cells and antibody responses to protein antigens , 2016, eLife.

[21]  Suzanne F. Jones,et al.  Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.

[22]  Jeffrey J Delrow,et al.  Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. , 2016, Immunity.

[23]  T. Kaisho,et al.  Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. , 2016, Cancer cell.

[24]  C. Glass,et al.  Affinity and dose of TCR engagement yield proportional enhancer and gene activity in CD4+ T cells , 2016, eLife.

[25]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[26]  M. Headley,et al.  Visualization of immediate immune responses to pioneer metastatic cells in the lung , 2016, Nature.

[27]  Yu Shyr,et al.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.

[28]  S. Kaech,et al.  The multifaceted role of CD4+ T cells in CD8+ T cell memory , 2016, Nature Reviews Immunology.

[29]  Monika S. Kowalczyk,et al.  Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells , 2015, Genome research.

[30]  Bin Shang,et al.  Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis , 2015, Scientific Reports.

[31]  L. Saveanu,et al.  Cross-Presentation of Cell-Associated Antigens by MHC Class I in Dendritic Cell Subsets , 2015, Front. Immunol..

[32]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[33]  Michael Poidinger,et al.  Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow , 2015, Nature Immunology.

[34]  Xiaodi Wu,et al.  Klf4 expression in conventional dendritic cells is required for T helper 2 cell responses. , 2015, Immunity.

[35]  Evan Z. Macosko,et al.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets , 2015, Cell.

[36]  T. Lawrence,et al.  Homeostatic NF-κB Signaling in Steady-State Migratory Dendritic Cells Regulates Immune Homeostasis and Tolerance. , 2015, Immunity.

[37]  A. Regev,et al.  Spatial reconstruction of single-cell gene expression , 2015, Nature Biotechnology.

[38]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[39]  刘尧.  Prognostic value of tumorinfiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis , 2015 .

[40]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[41]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[42]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[43]  W. Weninger,et al.  CD326loCD103loCD11blo Dermal Dendritic Cells Are Activated by Thymic Stromal Lymphopoietin during Contact Sensitization in Mice , 2014, The Journal of Immunology.

[44]  Edward Y Kim,et al.  Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. , 2014, The Journal of clinical investigation.

[45]  P. Sharma,et al.  Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy , 2014, The Journal of experimental medicine.

[46]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  G. Plitas,et al.  Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy , 2013, The Journal of experimental medicine.

[48]  A. Iwasaki,et al.  CD301b⁺ dermal dendritic cells drive T helper 2 cell-mediated immunity. , 2013, Immunity.

[49]  Hongyu Zhao,et al.  Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells. , 2013, Immunity.

[50]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[51]  A. Korman,et al.  Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.

[52]  Miriam Merad,et al.  The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. , 2013, Annual review of immunology.

[53]  J. Allison,et al.  Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin , 2012, The Journal of experimental medicine.

[54]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[55]  Amin R. Mazloom,et al.  Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages , 2012, Nature Immunology.

[56]  Daigo Hashimoto,et al.  Deciphering the transcriptional network of the DC lineage , 2012, Nature Immunology.

[57]  M. Nussenzweig,et al.  Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage , 2012, The Journal of experimental medicine.

[58]  Ansuman T. Satpathy,et al.  Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages , 2012, The Journal of experimental medicine.

[59]  A. Rudensky,et al.  Regulatory T cells: mechanisms of differentiation and function. , 2012, Annual review of immunology.

[60]  G. Anderson,et al.  Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.

[61]  G. Koretzky,et al.  Dendritic Cells Induce Regulatory T Cell Proliferation through Antigen-Dependent and -Independent Interactions , 2010, The Journal of Immunology.

[62]  R. Blasberg,et al.  Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.

[63]  A. Brooks,et al.  Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells , 2009, Nature Immunology.

[64]  D. Koller,et al.  The Immunological Genome Project: networks of gene expression in immune cells , 2008, Nature Immunology.

[65]  Clare L. Bennett,et al.  Clearance of influenza virus from the lung depends on migratory langerin+CD11b− but not plasmacytoid dendritic cells , 2008, The Journal of experimental medicine.

[66]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[67]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[68]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[69]  Naděžda Brdičková,et al.  CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs , 2006, Nature.

[70]  Scott A. Brown,et al.  An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Bevan,et al.  CD8α+ Dendritic Cells Selectively Present MHC Class I-Restricted Noncytolytic Viral and Intracellular Bacterial Antigens In Vivo1 , 2005, The Journal of Immunology.

[72]  Guttorm Haraldsen,et al.  Primary antitumor immune response mediated by CD4+ T cells. , 2005, Immunity.

[73]  A. Thiel,et al.  The IκB Kinase Complex and NF-κB Actas Master Regulators of Lipopolysaccharide-Induced Gene Expressionand Control Subordinate Activation ofAP-1 , 2004, Molecular and Cellular Biology.

[74]  G. Belz,et al.  Helper T cells, dendritic cells and CTL Immunity , 2004, Immunology and cell biology.

[75]  J. Alferink,et al.  Compartmentalized Production of CCL17 In Vivo , 2003, The Journal of experimental medicine.

[76]  J. Sprent,et al.  Type I Interferon-mediated Stimulation of T Cells by CpG DNA , 1998, Journal of Experimental Medicine.

[77]  Y. Yanagawa,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L‐positive T cells in Peyer’s patches by FTY720‐induced lymphocyte homing , 1998, Immunology.

[78]  H. Kataoka,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. , 1998, Journal of immunology.

[79]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[80]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.